Compare Glenmark Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs AJANTA PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA AJANTA PHARMA GLENMARK PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 12.6 23.5 53.8% View Chart
P/BV x 1.8 4.1 43.6% View Chart
Dividend Yield % 0.5 0.8 63.0%  

Financials

 GLENMARK PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
AJANTA PHARMA
Mar-19
GLENMARK PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs7121,422 50.0%   
Low Rs484898 53.9%   
Sales per share (Unadj.) Rs349.6233.5 149.7%  
Earnings per share (Unadj.) Rs32.844.0 74.6%  
Cash flow per share (Unadj.) Rs44.352.2 85.0%  
Dividends per share (Unadj.) Rs2.009.00 22.2%  
Dividend yield (eoy) %0.30.8 43.1%  
Book value per share (Unadj.) Rs198.6255.1 77.9%  
Shares outstanding (eoy) m282.1788.02 320.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.75.0 34.4%   
Avg P/E ratio x18.226.4 69.1%  
P/CF ratio (eoy) x13.522.2 60.6%  
Price / Book Value ratio x3.04.5 66.2%  
Dividend payout %6.120.5 29.8%   
Avg Mkt Cap Rs m168,625102,081 165.2%   
No. of employees `00012.06.8 177.0%   
Total wages/salary Rs m20,5614,307 477.4%   
Avg. sales/employee Rs Th8,196.03,022.6 271.2%   
Avg. wages/employee Rs Th1,708.1633.4 269.7%   
Avg. net profit/employee Rs Th768.5569.1 135.0%   
INCOME DATA
Net Sales Rs m98,65520,554 480.0%  
Other income Rs m2,081211 987.4%   
Total revenues Rs m100,73620,765 485.1%   
Gross profit Rs m15,8585,664 280.0%  
Depreciation Rs m3,259721 452.2%   
Interest Rs m3,34612 28,844.0%   
Profit before tax Rs m11,3355,143 220.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7561,273 295.1%   
Profit after tax Rs m9,2503,870 239.0%  
Gross profit margin %16.127.6 58.3%  
Effective tax rate %33.124.8 133.9%   
Net profit margin %9.418.8 49.8%  
BALANCE SHEET DATA
Current assets Rs m66,96811,812 566.9%   
Current liabilities Rs m40,2113,776 1,064.8%   
Net working cap to sales %27.139.1 69.4%  
Current ratio x1.73.1 53.2%  
Inventory Days Days8377 107.7%  
Debtors Days Days8182 99.5%  
Net fixed assets Rs m33,32214,398 231.4%   
Share capital Rs m282175 160.9%   
"Free" reserves Rs m55,77022,277 250.3%   
Net worth Rs m56,05222,452 249.7%   
Long term debt Rs m35,7387 541,477.3%   
Total assets Rs m132,88826,962 492.9%  
Interest coverage x4.4444.3 1.0%   
Debt to equity ratio x0.60 216,893.9%  
Sales to assets ratio x0.70.8 97.4%   
Return on assets %9.514.4 65.8%  
Return on equity %16.517.2 95.7%  
Return on capital %17.823.0 77.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99810,682 589.8%   
Fx outflow Rs m22,8592,102 1,087.5%   
Net fx Rs m40,1408,580 467.8%   
CASH FLOW
From Operations Rs m13,2423,748 353.3%  
From Investments Rs m-6,990-2,228 313.7%  
From Financial Activity Rs m-7,387-1,475 501.0%  
Net Cashflow Rs m-2,97145 -6,572.6%  

Share Holding

Indian Promoters % 48.3 73.8 65.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 1.6 445.2%  
FIIs % 34.4 7.6 452.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.0 61.8%  
Shareholders   56,727 20,968 270.5%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS